(UHS) Universal Health - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US9139031002

Acute Care, Behavioral Health, Outpatient Services

Stock: Health Care Facilities
Age 35.8y

MCap 12,720m
Avg Vol 725K (152M USD)

Beta 0.654
Volatility 29.96%

EPS (Earnings per Share)

EPS CAGR: -42.55%
EPS Trend: 11.7%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: 8.81%
Rev. Trend: 98.5%

Last SUE: 3.02
Qual. Beats: 2

Dividends

Dividend Yield	0.41%
Yield on Cost 5y	0.64%
Yield CAGR 5y	0.00%
Payout Consistency	56.3%
Payout Ratio	3.9%

Risk via 5d forecast
Volatility	30.0%
Value at Risk 5%th	45.8%
Relative Tail Risk	-7.02%

Reward TTM
Sharpe Ratio	0.29
Alpha	-1.11
CAGR/Max DD	0.36

Character TTM
Hurst Exponent	0.619
Beta	0.654
Beta Downside	0.733

Drawdowns 3y
Max DD	35.64%
Mean DD	12.93%
Median DD	13.40%

Description: UHS Universal Health January 02, 2026

Universal Health Services, Inc. (NYSE: UHS) operates a network of acute-care hospitals and outpatient/behavioral-health facilities across the United States, organized into Acute Care Hospital Services and Behavioral Health Care Services segments. Its sites deliver a full suite of services-including general and specialty surgery, obstetrics, emergency care, radiology, oncology, and pharmacy-while also offering commercial health-insurance and a range of back-office management functions such as central purchasing and physician recruitment. Founded in 1978 and headquartered in King of Prussia, PA, UHS is classified under the Health Care Facilities sub-industry.

Key performance indicators that analysts watch include: (1) FY 2024 revenue of approximately $13.2 billion, up ~5 % YoY, driven by higher admission volumes and price-inflation adjustments; (2) an occupancy rate that has stabilized around 78 % after pandemic-related swings, which is above the industry median of ~73 %; and (3) a cash-flow conversion rate exceeding 80 %, supporting its aggressive acquisition pipeline. Primary economic drivers for the sector are an aging U.S. population, increasing demand for behavioral-health services, and the impact of Medicare/Medicaid reimbursement reforms on profit margins.

For a deeper quantitative look, see the ValueRay analysis of UHS.

Piotroski VR‑10 (Strict, 0-10) 8.0

Net Income: 1.38b TTM > 0 and > 6% of Revenue
FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.48 > 1.0
NWC/Revenue: 0.58% < 20% (prev 5.13%; Δ -4.55% < -1%)
CFO/TA 0.13 > 3% & CFO 1.95b > Net Income 1.38b
Net Debt (5.00b) to EBITDA (2.58b): 1.94 < 3
Current Ratio: 1.03 > 1.5 & < 3
Outstanding Shares: last quarter (65.0m) vs 12m ago -4.58% < -2%
Gross Margin: 90.34% > 18% (prev 0.90%; Δ 8944 % > 0.5%)
Asset Turnover: 114.4% > 50% (prev 107.4%; Δ 7.02% > 0%)
Interest Coverage Ratio: 12.90 > 6 (EBITDA TTM 2.58b / Interest Expense TTM 153.5m)

Altman Z'' 4.57

A: 0.01 (Total Current Assets 3.26b - Total Current Liabilities 3.16b) / Total Assets 15.34b
B: 0.51 (Retained Earnings 7.87b / Total Assets 15.34b)
C: 0.13 (EBIT TTM 1.98b / Avg Total Assets 14.85b)
D: 1.87 (Book Value of Equity 15.04b / Total Liabilities 8.05b)
Altman-Z'' Score: 4.57 = AA

Beneish M -2.98

DSRI: 1.06 (Receivables 2.59b/2.21b, Revenue 16.99b/15.42b)
GMI: 0.99 (GM 90.34% / 89.78%)
AQI: 0.94 (AQ_t 0.31 / AQ_t-1 0.33)
SGI: 1.10 (Revenue 16.99b / 15.42b)
TATA: -0.04 (NI 1.38b - CFO 1.95b) / TA 15.34b)
Beneish M-Score: -2.98 = A

ValueRay F-Score (Strict, 0-100) 77.86

1. Piotroski: 8.0pt
2. FCF Yield: 5.36%
3. FCF Margin: 5.59%
4. Debt/Equity: 0.71
5. Debt/Ebitda: 1.94
6. ROIC - WACC: 7.01%
7. RoE: 19.85%
8. Revenue Trend: 98.55%
9. EPS Trend: 11.74%

What is the price of UHS shares?

As of January 25, 2026, the stock is trading at USD 205.09 with a total of 540,291 shares traded.
Over the past week, the price has changed by +2.61%, over one month by -9.76%, over three months by -1.62% and over the past year by +8.44%.

Is UHS a buy, sell or hold?

Universal Health has received a consensus analysts rating of 3.79. Therefor, it is recommend to hold UHS.

Strong Buy: 7
Buy: 1
Hold: 11
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the UHS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	250.4	22.1%
Analysts Target Price	250.4	22.1%
ValueRay Target Price	223.4	8.9%

UHS Fundamental Data Overview January 19, 2026

P/E Trailing = 9.5136
P/E Forward = 8.658
P/S = 0.7486
P/B = 1.7419
P/EG = 1.87
Revenue TTM = 16.99b USD
EBIT TTM = 1.98b USD
EBITDA TTM = 2.58b USD
Long Term Debt = 3.95b USD (from longTermDebt, last quarter)
Short Term Debt = 813.5m USD (from shortTermDebt, last quarter)
Debt = 5.11b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.00b USD (from netDebt column, last quarter)
Enterprise Value = 17.72b USD (12.72b + Debt 5.11b - CCE 112.9m)
Interest Coverage Ratio = 12.90 (Ebit TTM 1.98b / Interest Expense TTM 153.5m)
EV/FCF = 18.66x (Enterprise Value 17.72b / FCF TTM 949.6m)
FCF Yield = 5.36% (FCF TTM 949.6m / Enterprise Value 17.72b)
FCF Margin = 5.59% (FCF TTM 949.6m / Revenue TTM 16.99b)
Net Margin = 8.09% (Net Income TTM 1.38b / Revenue TTM 16.99b)
Gross Margin = 90.34% ((Revenue TTM 16.99b - Cost of Revenue TTM 1.64b) / Revenue TTM)
Gross Margin QoQ = 90.78% (prev 90.22%)
Tobins Q-Ratio = 1.15 (Enterprise Value 17.72b / Total Assets 15.34b)
Interest Expense / Debt = 0.75% (Interest Expense 38.4m / Debt 5.11b)
Taxrate = 23.70% (117.8m / 496.9m)
NOPAT = 1.51b (EBIT 1.98b * (1 - 23.70%))
Current Ratio = 1.03 (Total Current Assets 3.26b / Total Current Liabilities 3.16b)
Debt / Equity = 0.71 (Debt 5.11b / totalStockholderEquity, last quarter 7.23b)
Debt / EBITDA = 1.94 (Net Debt 5.00b / EBITDA 2.58b)
Debt / FCF = 5.26 (Net Debt 5.00b / FCF TTM 949.6m)
Total Stockholder Equity = 6.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.26% (Net Income 1.38b / Total Assets 15.34b)
RoE = 19.85% (Net Income TTM 1.38b / Total Stockholder Equity 6.93b)
RoCE = 18.20% (EBIT 1.98b / Capital Employed (Equity 6.93b + L.T.Debt 3.95b))
RoIC = 13.11% (NOPAT 1.51b / Invested Capital 11.52b)
WACC = 6.10% (E(12.72b)/V(17.83b) * Re(8.32%) + D(5.11b)/V(17.83b) * Rd(0.75%) * (1-Tc(0.24)))
Discount Rate = 8.32% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.63%
[DCF Debug] Terminal Value 87.72% ; FCFF base≈952.5m ; Y1≈1.17b ; Y5≈2.00b
Fair Price DCF = 897.3 (EV 54.56b - Net Debt 5.00b = Equity 49.56b / Shares 55.2m; r=6.10% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 11.74 | EPS CAGR: -42.55% | SUE: -4.0 | # QB: 0
Revenue Correlation: 98.55 | Revenue CAGR: 8.81% | SUE: 3.02 | # QB: 2
EPS next Quarter (2026-03-31): EPS=5.30 | Chg30d=-0.057 | Revisions Net=-2 | Analysts=10
EPS next Year (2026-12-31): EPS=23.46 | Chg30d=-0.104 | Revisions Net=-2 | Growth EPS=+7.6% | Growth Revenue=+5.0%

Additional Sources for UHS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle